IMC CS4

Drug Profile

IMC CS4

Alternative Names: IMCCS4; LY-3022855

Latest Information Update: 20 Jul 2016

Price : $50

At a glance

  • Originator ImClone Systems
  • Developer AstraZeneca; Eli Lilly; ImClone Systems
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Colony-stimulating factor receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Prostate cancer; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
  • 01 Jun 2016 Phase-I clinical trials in Solid tumours (Combination therapy, Late-stage disease) in USA (IV) (NCT02718911)
  • 21 Mar 2016 Eli Lilly and AstraZeneca plan a phase Ia/Ib trial for Solid tumours (Late-stage disease, Combination therapy) in USA, France, Belgium, Germany, Israel, Italy and Czech Republic (IV) (NCT02718911)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top